Study confirms effectiveness of the new Omikron booster

Biontech vaccine activated for booster vaccination against the current Corona variant JN.1 Production of adapted antibodies

01-Oct-2024 - The autumn wave of coronavirus is sweeping across Germany. Those affected mainly suffer from coughs, colds, sore throats and fever, but also from headaches, aching limbs, general weakness and shortness of breath. Because new SARS-CoV-2 variants and subtypes are constantly emerging, coronavirus ...

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

14-Feb-2024 - BioNTech SE and Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory ...

Helping the human body to fight diseases

Research into and development of mRNA-based therapeutics by a consortium of universities, the Fraunhofer-Gesellschaft, and BioNTech

16-Jun-2023 - A new funding program of the German Federal Ministry for Economic Affairs and Climate Action (BMWK) aiming to improve production capacities and fostering research into and the development of specialty lipids and other auxiliaries used in mRNA vaccines and mRNA pharmaceutical will give funding to ...

BioNTech and DualityBio form global strategic partnership

Focus on accelerated development of differentiated antibody-drug conjugates therapeutics for solid tumors

04-Apr-2023 - BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. (DualityBio), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”) therapeutics to treat patients with cancer and autoimmune diseases, announced that the companies have ...

New checkpoint antibody against cancer

BioNTech and OncoC4 announce strategic collaboration

22-Mar-2023 - BioNTech SE and OncoC4, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel biologicals for cancer treatment, announced that they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4’s ...

BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development

11-Jan-2023 - BioNTech SE andInstaDeep Ltd. announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a technology company in the field of artificial intelligence (“AI”) and machine learning (“ML”). The transaction includes a total upfront consideration of approximately ...

BioNTech and Ryvu Therapeutics enter partnership

Research collaboration for several small molecule immunotherapy programs

02-Dec-2022 - BioNTech SE and Ryvu Therapeutics S.A., a clinical-stage company developing oncology therapeutics announced that the companies have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreement for Ryvu’s STING ...

BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility

10-Oct-2022 - BioNTech SE announced that it has agreed a Letter of Intent with the State of Victoria in Australia on a strategic partnership between the State and BioNTech to collaborate on the research and development of potential mRNA-based vaccines and therapies. As part of the partnership, the parties will ...

BioNTech and Medigene announce global collaboration to advance T cell receptor immunotherapies against cancer

Medigene will receive EUR 26 million upfront from BioNTech

23-Feb-2022 - BioNTech SE and Medigene AG announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years. Medigene will contribute its proprietary TCR discovery platform for the ...

BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

Crescendo will receive $40 million upfront, including a cash payment and an equity investment from BioNTech

11-Jan-2022 - BioNTech SE and Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other ...